Navigation Links
Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA), announced today that it has submitted its pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment (SPA) procedure with the U.S. Food and Drug Administration (FDA).

Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase 3 clinical trial with its lead product ATPace. This trial is aimed at demonstrating clinical safety and efficacy of ATPace in treating paroxysmal supraventricular tachycardia, or PSVT, in emergency room patients. Upon successful completion of the trial, Duska intends to file a New Drug Application under section 505(b)(2).

The SPA is a process that provides for an official FDA evaluation of Phase 3 clinical study protocols. Once the SPA is agreed to by both the FDA and the trial sponsor, the SPA provides the sponsor with a binding written agreement that the design and analysis of the studies are adequate to support a license application submission if the study is performed according to the SPA and if the results are successful. The SPA agreement may only be changed by the sponsor company or the FDA by a written agreement, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety.

PSVT, one of the most common cardiac arrhythmias, is a rapid, regular heart rate originating in the atria. There are approximately 570,000 persons with PSVT in the United States alone, with an estimated 89,000 new cases diagnosed each year. Patients with PSVT may report palpitations, pounding in the chest, chest pressure or pain, weakness, shortness of breath, or dizziness. The heart rate in PSVT can range from 150-250 beats per minute.

ATPace, a stable liquid formulation of adenosine 5'-triphosphate (ATP) for intraven
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
3. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
4. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
5. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
6. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
7. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
10. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
11. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, ... and partner Auxilium Pharmaceuticals, Inc. today announced that the ... the European Medicines Agency (EMA) has adopted a positive ... for the treatment of adult men with Peyronie,s disease ... least 30 degrees at the start of therapy. ...
(Date:12/22/2014)...  Pfenex Inc. (NYSE MKT: PFNX) today announced the ... filed and is now open and that this program ... Health and Human Services (HHS), through the Biomedical Advanced ... extremely pleased to have the IND now active for ... milestone in our company,s partnership with BARDA as we ...
(Date:12/19/2014)... 2014 TODAY, AEGATE, the leader ... announced the appointment of Peter Fox as ... Channels and Partner Officer. Peter has served ... its acquisition by Oracle in 2011. Prior ... Geneva and subsequently Convergys, a world renowned ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4
... Pharmasset, Inc. (Nasdaq: VRUS ) announces that ... held May 2 to 4, 2011 at the InterContinental Hotel, ... Healthcare Conference being held May 10 to 12, 2011, at ... President and Chief Executive Officer, will provide an overview of ...
... April 28, 2011 Biodesix announces the enrollment of ... Addario Lung Cancer Medical Institute (ALCMI, pronounced as "Alchemy"). ... is recruiting a minimum of 250 subjects over two ... United States. The study collects biospecimens and data from ...
Cached Medicine Technology:Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3Biodesix Supports Unique Lung Cancer Research Initiative 2Biodesix Supports Unique Lung Cancer Research Initiative 3
(Date:12/22/2014)... Angeles, CA (PRWEB) December 22, 2014 ... reputable PALS, BLS and ACLS online certification provider, are ... http://www.acls-pals-bls.com . The updated site now features a ... easier than ever to use. , As a ... peoples’ information is now consolidated into a single page ...
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 22, 2014 Physicians in China are ... the treatment of non-Hodgkin’s lymphoma (NHL), according to a ... global healthcare consulting firm. MabThera is the only biologic ... most common form of NHL. , According to Kantar ... the incidence of NHL in China has been growing ...
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare transformation, ... Yarrington as Vice President of Operations, Adam Wallace as ... President of Solutions. These new leaders are part of ... to support client demand for the company’s big data ... of its partner network. , Since the company ...
(Date:12/22/2014)... 2014 In recognition of Veteran’s Day, ... Hero Reward, a local organization that provides services to ... , Located on a couple hundred acres in the ... lodging, world class fishing, hunting, hiking, horseback riding, 4-wheeling, ... several years ago to support U.S. Service men and ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2
... variations that point to spectrum disorders , TUESDAY, March ... for brain proteins that seem to be linked to ... of the most comprehensive genetic analyses of association between ... spectrum disorder] risk," said Anthony Monaco, of the Wellcome ...
... ... Detox Protocol using Far Infrared. FIR therapy is a major key for returning us back ... ... Ph.D., RIET-1, a Doctor of Integrative Medicine and an Industrial Toxicologist, has dedicated a ...
... complications, costs, , TUESDAY, March 30 (HealthDay News) -- Current ... age 45, especially for those who are overweight, but new ... 30 and 45 for everyone . , When screening ... every year to five years, the average cost per quality-adjusted ...
... lung cancer per year in Germany are due to ... in the current edition of Deutsches rzteblatt International ... and his coauthors ( Dtsch Arztebl Int 2010; ... the results of relevant studies, the recently published S1 ...
... One in three South Asian, West Asian or Arab women ... say they have trouble accessing a doctor to address ... findings, from a new study by researchers at St. Michael,s ... finds this group and immigrant women and men are at ...
... ... Misunderstandings about proper use of antibiotics have the potential to ... report in the April issue of AJIC: American Journal of Infection ... Control and Epidemiology, Inc. (APIC). esearchers from Columbia University and MixedInk ...
Cached Medicine News:Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 3Health News:Diabetes Screening Should Start Sooner 2Health News:Diabetes Screening Should Start Sooner 3Health News:Minority women least likely to gain access to a doctor, study says 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 3Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 4Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 5
Stainless steel threaded Steinman Pins available in point types A,D, E, and F....
Round Bevel-Point Pin Sets available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Unite Device is the anterior alternative to the ... device features the same 70% fenestrations as Ray ... is paramount in the formation of new bone. ... system promotes load sharing between the device and ...
Medicine Products: